SETTLEMENTS OF ACCOUNTS

From 1st April 2020 to 31st March 2021

Concord Biotech Japan K.K.

Atsushi SATO, President

OHMURA Tax Account Office

2029–2 Ichihama, Numazu, Shizuoka, JAPAN \mp 410 – 0312

静岡県沼津市原2029-2

大村税理士事務所程理士大村勇次

TEL 0559(67)6318



BALANCE SHEETS

As at 31st March 2021

CONCORD BIOTECH JAPAN K.K.

JPY

| Assets | | Liabilities | | |
|---------------------------------|-------------|-----------------------------------|-------------|--|
| Current assets | 269,920,527 | Current liabilities | 115,562,348 | |
| Cash and deposit | 42,534,647 | Account payable-trade | 113,300,000 | |
| Promissory notes [Receivable] | 83,160,000 | Short-term borrowing | 452,084 | |
| Account Receivable | 95,620,000 | Account payable-other | 765,316 | |
| Allowance for doubtful accounts | -1,787,800 | Deposits payable | 1,044,948 | |
| Product inventory | 46,261,176 | | | |
| Advance payment | 6,800 | | 1 | |
| Prepaid expenses | 370,804 | Long-term liabilities | 95,579,180 | |
| Consumption Taxes Receivable | 3,754,900 | Long-term borrowings | 95,579,180 | |
| Fixed assets | 244,555 | Liabilities total: | 211,141,528 | |
| Fixed assets | 234,555 | Net Equity | | |
| Machinery | 234,555 | Stockholders equity | 59,023,554 | |
| Investment and other assets | 10,000 | Capital | 20,000,000 | |
| Capital | 10,000 | Accumulated earnings | 39,023,554 | |
| | - | Other accumulated earnings | 39,023,554 | |
| | | Brought down accumulated earnings | 39,023,554 | |
| , | | (Net gain of current period) | 27,641,202 | |
| * | | Net equity total | 59,023,554 | |
| Asset total: | 270,165,082 | Liabilities and net equity total: | 270,165,082 | |





INCOME STATEMENT

From 1st April 2020 to 31st March 2021

| CONCORD BIOTECH JAPAN K.K. | | JPY |
|-----------------------------------------------------|-------------|-----------------------------------------|
| Net sales | | |
| Amount of sales | 276,650,000 | - TO |
| Overseas sales | 227,500,000 | |
| Net sales total | | 504,150,000 |
| Cost of sales | | |
| Imported Purchases | 267,499,750 | |
| Import charges | 354,212 | |
| Export charges | 232,053 | |
| Overseas Purchases | 200,200,000 | |
| Total | 468,286,015 | * . a. |
| Closing [End] inventory | 46,261,176 | |
| Cost of sales | | 422,024,839 |
| Gross profit | | 82,125,161 |
| Selling, general & administrative expenses | | |
| Total of selling, general & administrative expenses | | 56,812,123 |
| Sales gain | | 25,313,038 |
| | | - |
| Non-operating gain | | |
| Interest received | 374 | |
| Divident received | 250 | |
| Miscellaneous income | 2,000,452 | |
| Non-operating gain total | | 2,001,076 |
| | | |
| Non-operating loss | | |
| Interest paid | 127,438 | * |
| Discount expense | 612,199 | |
| Non-operating loss total | | 739,637 |
| Ordinary gain | | 26,574,477 |
| | | , |
| Special profit | | |
| Reversal of allowance for doubtful accounts | 1,066,725 | |
| Special profit total | | 1,066,725 |
| | 1 | |

atsustic Seco

Net gain

稀沼

Gain of income before income tax

27,641,202

27,641,202

Selling, General & Administrative Expenses

From 1st April 2020 to 31st March 2021

| CONCORD BIOTECH JA | PAN | K.K. |
|--------------------|-----|------|
|--------------------|-----|------|

JPY

| Payments for directors, A.Sato and Utako Sato | 22,410,000 | |
|---------------------------------------------------|------------|------------|
| Salary | 21,051,000 | a a |
| Contribution to Health Insurance & Pension Fund | 3,272,489 | |
| Welfare expense | 41,602 | - |
| Transportation | 14,479 | |
| Traveling expenses | 691,220 | |
| Communications | 732,492 | |
| Office Supplies [like Printing & Stationery etc.] | 327,526 | |
| Utilities | 226,720 | _ |
| Books and subscription | 4,600 | |
| Bank charges | 327,438 | |
| Payments to Consultants | 614,000 | |
| Deprecitaion expenses | 117,101 | |
| Office rent | 3,780,000 | |
| Taxes, Stamp Duty on Promissory Notes and Oth | 1,413,656 | - |
| Provision of allowance for doubtful accounts | 1,787,800 | |
| Total: | | 56,812,123 |



